Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2017 /
COMBI-AD: Dabrafenib plus trametinib in advanced melanoma

8th - 12th Sep 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.09.17
Views: 922

Dr Axel Hauschild - University Hospital, Schleswig-Holstein, Germany

Dr Hauschild speaks with ecancer at the ESMO 2017 Congress in Madrid about the COMBI-AD trial looking into the use of dabrafenib plus trametinib for patients with high-risk, stage III, BRAF V600E/K–mutant melanoma without prior anticancer therapy. 

Dr Hauschild goes on to discuss the results stating that relapse-free survival benefit with dabrafenib plus trametinib was observed across all patient subgroups. Dabrafenib plus trametinib also improved secondary endpoints of overall survival, distant metastasis-free survival, freedom from relapse.

For more information watch the press conference here, or read our news coverage here.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence